Biodesix Inc (BDSX) · Nov 5, 2026 · Earnings
Miss — Revenue $24.0M vs ~$27.5M consensus
Biodesix’s Q3 earnings show healthy diagnostic test growth, but a major revenue miss and sharp 2026 guidance cut expose execution delays.
Biodesix is scaling blood-based lung diagnostics while expanding into digital diagnostics and molecular residual disease monitoring; the immediate challenge is converting that product and clinical momentum into repeatable commercial growth. Before this filing, the company had maintained a 2026 revenue outlook of $108M-$114M, while published Q3 revenue consensus was approximately $27.5M.
The quarter materially missed the revenue bar. Revenue reached $24.0M, up 10% year over year, but was roughly 12.5% below consensus; the shortfall was concentrated in weaker-than-expected execution rather than a collapse in diagnostic demand.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Total revenue (Financial Highlights) | $24.0M (-12.5%) | $21.8M | ~$27.5M consensus |
| Diagnostic Testing revenue (Financial Highlights) | $23.0M (+16%) | $19.8M | |
| Test volume (Financial Highlights) | 19,400 (+24%) | 15,600 | |
| Gross margin (Financial Highlights) | 81% | 81% | |
| Net loss (Statements of Operations) | $(8.0)M (+8%) | $(8.7)M | |
| Adjusted EBITDA loss (Reconciliation) | $(3.9)M (+16%) | $(4.6)M | |
| FY2026 revenue guidance (2026 Financial Outlook) | $101M-$103M | $108M-$114M prior |
Core diagnostic demand held up, but monetization and execution weakened. Diagnostic Testing revenue grew 16% and volumes grew 24%, yet lower average revenue per test diluted the benefit, while Development Services revenue fell to $1.0M from $1.9M because projects started and were recognized later than expected.
The guidance cut is the clearest change to the business story. Management reduced the full-year revenue range by $7M-$11M, acknowledging fewer productive sales representatives, heavier seasonality, and delayed customer-dependent projects. The roughly 15% midpoint growth target now implies a substantially slower year than the previously expected 25% midpoint growth.
Loss improvement does not offset the top-line reset. Gross margin stayed high at 81%, and both net loss and Adjusted EBITDA loss improved year over year, but the company remains loss-making and used $6.3M of at-the-market proceeds during the quarter even as cash declined from the prior quarter.
Bottom line: Biodesix still has real volume growth and improving operating losses, but this filing resets the near-term growth story lower. The issue is execution and timing today; the magnitude of the guidance cut makes it a clearly negative earnings event rather than a routine slowdown.
Q4 results, expected early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!